Related:

  1. Seminar

    Lunch and learn at UEL: the seven deadly sins of market access in the U.S.

At a glance

Serving nearly 400 medical device, pharmaceutical and biotech companies

Baker Tilly works with private and public life sciences companies, private equity firms and portfolio companies to help meet company goals in all stages of the lifecycle – from launch to growth to maturity to exit. Our work with stakeholders across the industry spectrum, including health plans, providers and life sciences companies, provides us with a 360-degree industry view to address your needs.

Life sciences companies develop new and enhance existing technologies to better patients’ lives. Baker Tilly provides solutions to the challenges and opportunities inherent in each stage of a company’s lifecycle, helping facilitate better patient health outcomes and providing our clients with peace of mind regarding their financial operations.

Baker Tilly’s comprehensive industry knowledge, deep experience and strategic relationships can help life sciences companies grow their business. Our team provides actionable ideas and solutions drawn from our work with hundreds of life sciences companies nationwide, including medical device, pharmaceutical and biotech companies. Team members have been published in multiple peer-reviewed publications and medical journals, demonstrating their expertise in helping companies achieve their objectives.

Our life sciences team can help with 

Market access – Using patient data, clinical utility/economic studies and relationships with providers and health plans, we develop value propositions for companies’ technology that demonstrate a compelling story to insurance companies and providers’ customers.

Financial health – By helping establish a solid foundation of risk assessment and mitigation strategies, tax minimization approaches and effective implementation of new financial regulations, we help companies attain the financial health that is important to investors and lenders.

Capital requirements – The capital required for funding ongoing operations and new product development is available through various sources. Utilizing our relationships with and understanding of these sources can help companies achieve the desired financing outcome.

Video

About our life sciences practice

Life sciences industry leader Mike McKee and healthcare/life sciences consulting leader David Gregory share how Baker Tilly is making a difference for life sciences companies during all stages of their lifecycle, including helping companies address reimbursement challenges, grow their presence internationally and understand capital requirements.

Since day one, I have been happy with the Baker Tilly team. Their technical expertise has been instrumental in helping us manage numerous unique and complex transactions, both in the U.S. and overseas. 
Scott Longval, CFO, IntriCon Corporation

Services

  • Assurance
  • Commercial excellence
  • Clinical operations excellence
  • Credits and Incentives
  • Dashboarding/analytics
  • Government contracting and pricing
  • Internal audit
  • Obtaining market access
  • Private equity
  • Risk and cybersecurity
  • Tax
  • Transaction advisory
Baker Tilly gives you all of the expertise and technical comfort you get from a Big Four firm, but they are more responsive and flexible to work with. The team selected for our engagement has significant manufacturing expertise that meets our needs. I don’t have to teach them about our business.
Ed Meyer, CFO, NPI Medical
New Markets Tax Credit program: how it works
Case study

Budget impact model helps medical device company gain trust with hospitals to adapt new breast cancer technology

See how Baker Tilly helped a medical device company better articulate the value proposition of a new technology for hospitals that could be a break-through in breast cancer detection and management.

Vascular Solutions testimonial